Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G.

Oncologist. 2013;18(2):148-56. doi: 10.1634/theoncologist.2012-0302. Epub 2013 Jan 23. Review.

2.

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

Colmers IN, Bowker SL, Majumdar SR, Johnson JA.

CMAJ. 2012 Sep 4;184(12):E675-83. doi: 10.1503/cmaj.112102. Epub 2012 Jul 3.

3.

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

Zhu Z, Shen Z, Lu Y, Zhong S, Xu C.

Diabetes Res Clin Pract. 2012 Oct;98(1):159-63. doi: 10.1016/j.diabres.2012.05.006. Epub 2012 Jun 16.

PMID:
22705039
4.

Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.

Colmers IN, Bowker SL, Johnson JA.

Diabetes Metab. 2012 Dec;38(6):475-84. doi: 10.1016/j.diabet.2012.06.003. Epub 2012 Oct 5. Review.

5.

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.

Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA.

Hepatology. 2012 May;55(5):1462-72. doi: 10.1002/hep.25509.

PMID:
22135104
6.

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A.

Am J Cardiovasc Drugs. 2011;11(2):115-28. doi: 10.2165/11587580-000000000-00000. Review.

PMID:
21294599
7.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

8.

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK.

Br J Clin Pharmacol. 2014 Aug;78(2):258-73. doi: 10.1111/bcp.12306.

9.

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A.

JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.

PMID:
26197187
10.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
11.

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E.

Acta Diabetol. 2014 Feb;51(1):91-101. doi: 10.1007/s00592-013-0504-8. Epub 2013 Jul 14.

PMID:
23851465
12.

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS.

Drug Saf. 2013 Aug;36(8):643-9.

PMID:
23797604
13.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
14.

Pioglitazone and cancer: angel or demon?

Kostapanos MS, Elisaf MS, Mikhailidis DP.

Curr Pharm Des. 2013;19(27):4913-29. Review.

PMID:
23278487
15.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
16.

Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study.

Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S.

Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):343-50. doi: 10.1002/pds.1883.

PMID:
19998318
17.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

18.

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.

Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G.

Oncologist. 2012;17(6):813-22. doi: 10.1634/theoncologist.2011-0462. Epub 2012 May 29. Review.

19.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
20.

Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.

He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y.

Tumour Biol. 2014 Mar;35(3):2095-102. doi: 10.1007/s13277-013-1278-x. Epub 2013 Oct 4.

PMID:
24092576
Items per page

Supplemental Content

Write to the Help Desk